Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEN-001 + pembrolizumab + mFOLFOX
- Development stage
- Unknown
- Lead developer
- Genome & Company
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
GEN-001 + pembrolizumab + mFOLFOX is a combination investigational drug regimen consisting of GEN-001, an oral microbiome therapeutic, pembrolizumab (a PD-1 immune checkpoint inhibitor), and mFOLFOX (modified FOLFOX, a chemotherapy regimen of oxaliplatin, folinic acid (leucovorin), and fluorouracil). GEN-001 is designed to modulate the gut microbiome to enhance antitumor immunity. Pembrolizumab blocks the PD-1 receptor on T cells, enhancing immune system activity against cancer. mFOLFOX is a standard chemotherapeutic regimen used primarily for colorectal and other gastrointestinal cancers, working by damaging DNA or interfering with cell division, especially in rapidly dividing cancer cells[1][3][4][5]. The combination is being studied in advanced cancers to harness synergistic cytotoxic, immunomodulatory, and microbiome-mediated effects.
- Other names
- GEN-001 + pembrolizumab + mFOLFOX
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on GEN-001 + pembrolizumab + mFOLFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEN-001 + pembrolizumab + mFOLFOX.